Pemetrexed is Mildly Active with Good Tolerability for Treatment of Patients with Colorectal Cancer

作者：Huiqing Zhang, Changhong Lian, Yaodong Ping, Wenbin Song, Qingpu Lu, Shuzhe Xie, Lin Tao, Lin-Zhong Cheng · 发表于：Asian Pacific Journal of Cancer Prevention · 年份：2014 · DOI：10.7314/apjcp.2014.15.19.8391 · 被引用次数：2 · 研究领域：Colorectal Cancer Treatments and Studies、Lung Cancer Treatments and Mutations、PARP inhibition in cancer therapy

PURPOSE: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed based salvage chemotherapy for treatment of patients with metastatic colorectal cancer. METHODS: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with colorectal cancer were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. RESULTS: For pemetrexed based regimens, 4 clinical studies including 201 patients with advanced colorectal cancer were considered eligible for inclusion. The analysis suggested that, in all patients, pooled RR was 20.4% (41/201). Major adverse effects were neutropenia, anorexia, fatigue, and anemia. No treatment related death occurred with pemetrexed based treatment. CONCLUSION: This systematic analysis suggests that pemetrexed based regimens are associated with mild activity with good tolerability in treating patients with metastatic colorectal cancer.